Turn Biotechnologies Acquires ARMMs to Enhance Their Epigenetic Therapy Reach
Deal News | Mar 26, 2025 | PR Newswire Cision Turn Biotechnologies, Inc.
Turn Biotechnologies, a trailblazer in the epigenetic reprogramming sector, has announced the acquisition of the innovative ARMMs (ARRDC1 Mediated Microvesicles) technology. This acquisition is set to significantly enhance the company's ability to deliver epigenetic therapies safely and accurately across a wider range of organs, tissues, and cells. The ARMMs technology promises precision medicine through targeted, non-viral vesicular delivery, complementing Turn Bio's existing eTurna platform, which uses mRNA to translate proteins that combat age-related conditions. The ARMMs technology was licensed from Harvard University along with assets from Vesigen Therapeutics. This deal enriches Turn Bio's arsenal, enabling it to advance its therapeutic candidates, particularly those targeting ophthalmology and rejuvenation of immune cells. The acquisition also aligns with Turn Bio's ongoing research in dermatology, ophthalmology, and immunology, potentially attracting investor attention from notable entities like Bayer Healthcare LLC and others. With the integration of ARMMs, Turn Bio aims to lead the future of regenerative medicine, emphasizing the colossal potential of epigenetics.
Sectors
- Biotechnology
- Pharmaceuticals
- Healthcare
Geography
- United States – Turn Biotechnologies is based in Mountain View, California, and the ARMMs technology was licensed from Harvard University in Massachusetts.
Industry
- Biotechnology – The article is centered on Turn Biotechnologies, a company involved in biotechnology, focusing on epigenetic reprogramming therapies.
- Pharmaceuticals – The development and delivery of candidate drugs for ophthalmological, dermatological, and immunology therapies align with the pharmaceuticals sector.
- Healthcare – Turn Biotechnologies is working towards new methods for treating age-related diseases and improving healthcare outcomes through innovative therapies.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Turn Biotechnologies, Inc. | Acquiring Company | Company | A pioneer in epigenetic reprogramming therapies, focusing on tissue regeneration at the cellular level. |
| Harvard University | Licensor | Institution | Provided the license for ARMMs technology that Turn Biotechnologies acquired. |
| Vesigen Therapeutics | Selling Company | Company | Originating developer of the ARMMs technology under license from Harvard University. |
| Bayer Healthcare LLC | Investor | Company | An important investor interested in the ARMMs technology acquisition by Turn Biotechnologies. |
| Morningside Group Ltd. | Investor | Company | An investor observing the technological advancements at Turn Biotechnologies. |
| Alexandria Ventures | Investor | Company | One of the key investment entities interested in Turn Biotechnologies’ developments. |
| Anja Krammer | CEO | Person | Chief Executive Officer of Turn Biotechnologies, driving the strategy around this acquisition. |